Eclipsing Toxicity,Enhancing Efficacy:Clofazimine's Vanguard in the Realm of Anti-PD-1 and CTLA-4 Immunotherapy  

作　　者：Ruirong Tan Junning Zhao Quazi T.H.Shubhra 

机构地区：[1]Translational Chinese Medicine Key Laboratory of Sichuan Province,Sichuan Institute for Translational Chinese Medicine,Sichuan Academy of Chinese Medicine Sciences,Chengdu 610041,China [2]National Medical Products Administration (NMPA),Beijing 100038,China [3]Institute of Chemistry,University of Silesia in Katowice,Szkolna 9,40-003 Katowice,Poland.

出　　处：《Research》2025年第1期631-633,共3页研究(英文)

摘　　要：Cancer’s unrelenting grip on global health drives the relentless pursuit of innovative therapies to improve patient outcomes[1].Among these advancements,immunotherapy—specifically immune checkpoint blockade(ICB)—has emerged as a transformative approach by harnessing the body’s own immune system to effectively target and eradicate tumors[2].Nivolumab[anti-programmed death receptor-1(PD1),marketed as Opdivo]and ipilimumab[anti-Cytotoxic T lymp hocyte-associated antigen-4(CTLA-4),known commercially as Yervoy]are prominent examples of ICB therapy.However,their effectiveness is sometimes overshadowed by severe immune-related adverse events(irAEs)that affect patient quality of life and limit wider application[3].

关 键 词：EFFICACY immune checkpoint blockade icb immune system CLOFAZIMINE 

分 类 号：R730.51[医药卫生—肿瘤]